Barclays’s KalVista Pharmaceuticals KALV Stock Holding History

Barclays’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,800	Closed	-$574K	–	5611
2025 Q2	$574K	Buy	+50,800	New	+$621K	﹤0.01%	3687

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's KALV Position: Q2 2026 in Review

Barclays sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 537,061 shares — an estimated $10.8M sold.

Barclays first reported a position in KALV in Q2 2015 and held it in 35 quarters. The position peaked at $11.3M in Q4 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Barclays reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Barclays sold 537,061 KalVista Pharmaceuticals shares in Q2 2026, an estimated $10.8M.
Barclays first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 35 quarters.
Barclays's KalVista Pharmaceuticals position peaked at $11.3M in Q4 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.